Characterisation of circulating chromogranin A in human cancer patients

A. Corti, A. Gasparri, F. X. Chen, M. Pelagi, A. Brandazza, A. Sidoli, A. G. Siccardi

Research output: Contribution to journalArticle

Abstract

The structure of circulating chromogranin A (CgA) of phaeochromocytoma patients was characterised and compared with that of CgA extracted from rumours. Size exclusion chromatography experiments provided evidence that CgA is present in the blood of different patients, as well as in tumour extracts, as multiple forms having different hydrodynamic sizes of 600 kDa (CgA-I), 100 kDa (CgA-II) and 55 kDA (CgA-III). The amount of each CgA form as a proportion of the total antigenic material was different in different patients. Western blot analysis of chromatographic fractions indicated that these forms are made up by polypeptides of similar molecular weight (about 60-70 kDa). All CgA forms express the epitopes recognised by two monoclonal antibodies (A11 and B4E11), directed against residues 68-70 and 81-90 of human CgA. However, their relative immunoreactivity was markedly different. No evidence for the presence of multimeric complexes in the CgA-I fraction was obtained by various immunological and biochemical methods. These results suggest that circulating CgA in phaeochromocytoma patients consists of at least three forms that appear to be made up by polypeptides with similar molecular weight and different hydrodynamic properties and immunoreactivity. We hypothesise that different conformations and shapes contribute to the heterogeneity of circulating CgA.

Original languageEnglish
Pages (from-to)924-932
Number of pages9
JournalBritish Journal of Cancer
Volume73
Issue number8
Publication statusPublished - Apr 1996

Keywords

  • Chromogranin
  • Endrocine/neuroendocrine tumours
  • Monoclonal antibody
  • Size exclusion chromatography
  • Tumour marker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Characterisation of circulating chromogranin A in human cancer patients'. Together they form a unique fingerprint.

Cite this